Flow Neuroscience Raises 1.1M USD in Seed Round Lead by Khosla Ventures to Develop a Device to Treat Depression
STOCKHOLM, January 26, 2018 -- (Healthcare Sales & Marketing Network) -- Flow Neuroscience, a Sweden-based medtech company is developing a new treatment for depression combining brain stimulation with behavioral therapy. They have now secured a $1.1 milli... Devices, Neurology, Venture Capital Flow Neuroscience, Major Depressive Disorder, neuromodulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

Gamma Knife Radiosurgery Hits Half-century Mark With Over a Million Patients Treated
Elekta's constantly evolving Leksell Gamma Knife a seemingly permanent - often best - option for treating wide range of intracranial disorders STOCKHOLM, Jan. 26, 2018 -- (Healthcare Sales & Marketing Network) -- The first patient to have Leksell Gamma... Devices, Oncology Elekta, Leksell, Gamma Knife, radiosurgery, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

ESSA Announces Management Team Change
HOUSTON and VANCOUVER, Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Ch... Biopharmaceuticals, Oncology, Personnel ESSA Pharma, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

BIOLASE Rejects Frivolous, Abusive Patent Litigation
IRVINE, Calif., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser company, today released the following statement in response to the latest attempt by CAO Group, Inc. to use patent li... Devices, Dental, Litigation BIOLASE, CAO Group (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

Vascular Insights(R) Announces New Chief Executive Officer
James P. Ott to Join Vascular Insights® as President & CEO QUINCY, Mass., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Vascular Insights® announced that its Board of Directors has appointed James P. Ott as President and CEO. Ji... Devices, Interventional, Personnel Vascular Insights, ClariVein, peripheral vascular disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 26, 2018 Category: Pharmaceuticals Source Type: news

IRIS Announces Changes and Additions to Its Executive Leadership Team
Imaging Systems Leader Eclipses 250,000 Diabetic Retinopathy Examinations and Positions Itself for Continued Growth PENSACOLA, Fla., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Intelligent Retinal Imaging Systems (IRIS), the industry lea... Devices, Ophthalmology, Personnel Intelligent Retinal Imaging Systems, diabetic retinopathy, telemedicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2018 Category: Pharmaceuticals Source Type: news

Aptima(R) HBV Quant Assay for Quantitation of Hepatitis B Viral Load Receives PMA Approval
Aptima assay portfolio rapidly expanding with the addition of tests to quantitate HIV-1, HCV and HBV now available on the fully automated Panther system MARLBOROUGH, Mass., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Hologic, Inc. (Nasda... Diagnostics, FDA Hologic, Aptima, HBV Quant Assay, Hepatitis B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2018 Category: Pharmaceuticals Source Type: news

BioPharma Veterans Launch New Oncology Company
Partner Therapeutics to focus on commercial and late-stage cancer therapies BOSTON, Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Biotech and pharmaceutical executives Robert Mulroy and Dr. Debasish Roychowdhury announced today the launch ... Biopharmaceuticals, Oncology, Personnel Partner Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2018 Category: Pharmaceuticals Source Type: news

Ellen M. Zane Rejoins Haemonetics Board of Directors
BRAINTREE, Mass., Jan. 25, 2018 -- (Healthcare Sales & Marketing Network) -- Haemonetics Corporation (NYSE: HAE) announced the election of Ellen M. Zane to its Board of Directors. Zane is a nationally renowned health care leader with more than 30 years of... Devices, Surgery, Personnel Haemonetics, plasma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2018 Category: Pharmaceuticals Source Type: news

Neuspera Medical Announces Initial Close of $26M Series B Equity Financing
Global Healthcare Investor 6 Dimensions Capital Leads Round SAN JOSE, Calif., Jan. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced th... Devices, Neurology, Venture Capital, Personnel Neuspera Medical, neuromodulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace(R) Cream
DUBLIN, Jan. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for the generic version of Estrace® Cream (estradiol va... Biopharmaceuticals, Generics, FDA Perrigo, Estrace, estradiol (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo(R) Gel
DUBLIN, Jan. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo®... Biopharmaceuticals, Generics, FDA, Product Launch Perrigo, Epiduo, adapalene, benzoyl peroxide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Boston Scientific Announces Investment and Acquisition Option Agreement with Millipede, Inc.
Millipede, Inc. is developing the IRIS Transcatheter Annuloplasty Ring System to treat severe mitral regurgitation MARLBOROUGH, Mass., Jan. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced ... Devices, Interventional, Cardiology, Mergers & Acquisitions Boston Scientific, Millipede, Transcatheter, Annuloplasty Ring (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
BOTHELL, Washington and VANCOUVER, British Columbia, Jan. 24, 2018 -- (Healthcare Sales & Marketing Network) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization o... Biopharmaceuticals, Licensing Achieve Life Sciences, cytisine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Advicenne Appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs
Dr Law's appointment paves the way for Advicenne's United States operations NÎMES, France, January 24, 2018 -- (Healthcare Sales & Marketing Network) -- Advicenne (Euronext:ADVIC), a late-stage biopharmaceutical company developing pediatric frien... Biopharmaceuticals, Personnel Advicenne, distal Renal Tubular Acidosis, ADV7103 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 24, 2018 Category: Pharmaceuticals Source Type: news

Skyhawk Therapeutics Launches With $8 Million in Seed Financing to Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA Expression
The company's founders are leading experts in the development of small molecule therapeutics for RNA-driven disease. Skyhawk's initial pipeline is focused on neurological and cancer indications WALTHAM, Mass., Jan. 23, 2018 -- (Healthcare Sales & Market... Biopharmaceuticals, Venture Capital, Personnel Skyhawk Therapeutics, RNA expression (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

TECHLAB Receives FDA 510(k) Clearance To Market CAMPYLOBACTER QUIK CHEK(TM) and CAMPYLOBACTER CHEK(TM) Tests
Tests Help Clinicians Diagnose Diarrhea Caused by Campylobacter Bacteria BLACKSBURG, Va., Jan. 23, 2018 -- (Healthcare Sales & Marketing Network) -- TECHLAB, Inc., a leading developer and manufacturer of rapid non-invasive diagnostic tests for gastroin... Diagnostics, Gastroenterology, Product Launch TECHLAB, CAMPYLOBACTER, QUIK CHEK (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
CAMBRIDGE, Mass., Jan. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, axonal degeneration (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 23, 2018 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Vision Expands Parameter Offering for 1-DAY ACUVUE(R) MOIST Brand Contact Lenses for ASTIGMATISM
Nearly half of vision-corrected patients has astigmatism in at least one eye,(1) and full correction can provide improved visual quality of life(2) JACKSONVILLE, Fla., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson Vision ... Devices, Ophthalmology, Product Launch Johnson & Johnson, Johnson & Johnson Vision, ACUVUE MOIST (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology
SAN FRANCISCO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced the appointment of Hicham Alaoui, Ph.D., as Senior Vice President of Discov... Biopharmaceuticals, Personnel Symic Bio, matrix-targeting biotherapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Hologic's Cynosure Division Launches TempSure(TM) Envi
Superior Radiofrequency Treatment Minimizes Fine Facial Lines and Wrinkles, Tightens Skin Through Soft Tissue Coagulation, and Improves the Appearance of Cellulite MARLBOROUGH, Mass., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Hologic's... Devices, Dermatology, Product Launch Hologic, TempSure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio(R) (lotilaner) to Treat and Protect Against Ticks and Fleas
New monthly oral tick and flea treatment offers easy dosing, efficacy in as little as four hours, all month long GREENFIELD, Ind., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Today, Elanco Animal Health, a division of Eli Lilly and Comp... Biopharmaceuticals, FDA Elanco Animal Health, Eli Lilly, Credelio, lotilaner (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

AVACEN Medical Device for Autistic Spectrum Disorder Behavior Management Launched in Hong Kong
50% Discounted Launch Price Offered SAN DIEGO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- AVACEN Medical, Inc. (AVACEN) announced that it is launching sales of its AVACEN 100, an FDA-cleared and CE marked, class II dry-heat therapy medi... Devices, Product Launch AVACEN Medical, AVACEN 100, autistic spectrum disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Fred Colen Appointed Chief Executive Officer of Neovasc Inc.
NCOUVER, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its boa... Devices, Interventional, Cardiology, Personnel Neovasc , Reducer, Tiara, transcatheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
TARRYTOWN, N.Y., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization... Biopharmaceuticals, Dermatology, Regulatory Regeneron Pharmaceuticals, Sanofi, DUPIXENT, dupilumab, atopic dermatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Titan In Discussions With Braeburn Regarding U.S. Probuphine(R) Commercialization
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura¬ô long-ter... Biopharmaceuticals Titan Pharmaceuticals, Braeburn Pharmaceuticals, ProNeura, Probuphine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
TOKYO and SAN DIEGO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Vical Incorporated (NASDAQ: VICL) announced today that ASP0113, an investigat... Biopharmaceuticals Astellas Pharma, Vical , cytomegalovirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 22, 2018 Category: Pharmaceuticals Source Type: news

MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018 -- (Healthcare Sales & Marketing Network) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular disease... Biopharmaceuticals, Cardiology, Personnel MyoKardia, cardiomyopathy, mavacamten (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

UPM Pharmaceuticals appoints Chris Curtin as Chief Operating Officer
40 years of industry experience in domestic and international markets related to Quality, Manufacturing, Supply Chain, Pharmaceutical Technology and Engineering BRISTOL, Tenn., Jan. 19, 2018 -- (Healthcare Sales & Marketing Network) -- UPM Pharmaceutic... Biopharmaceuticals, Personnel UPM Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

Gathering Together World-Renowned Medical Device Manufacturing Suppliers, Medtec China Helps to Propel the Medical Device Localization Process
SHANGHAI, Jan. 19, 2018 -- (Healthcare Sales & Marketing Network) -- To deliver a boost to the Medical Device Industry in China, the Chinese government has proactively launched several policies directed at medical device innovation which focus on speeding... Devices, Regulatory Medtec China (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium WOODCLIFF LAKE, N.J., Jan. 19, 2018 -- (Healthcare Sales & Marketing ... Biopharmaceuticals, Oncology Eisai, REFLECT study, lenvatinib, Lenvima, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 19, 2018 Category: Pharmaceuticals Source Type: news

Clinical Genomics appoints Tadd Lazarus, M.D., as Chief Medical Officer
BRIDGEWATER, N.J., Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Clinical Genomics, a leading provider of cancer diagnostic solutions and liquid biopsy tests, today announced the appointment of Tadd Lazarus, M.D., as Chief Medical Officer. La... Diagnostics, Oncology, Personnel Clinical Genomics, colorectal cancer, COLVERA, liquid biopsy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

New Registry Launched to Track and Improve the Quality of Cancer Care Delivered in the U.S.
Quality Oncology Practice Initiative (QOPI®) Reporting Registry is a Joint Effort of Two Leading Oncology Societies ALEXANDRIA, Va., Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- A registry that tracks the quality of medical care provid... Devices, Oncology, Product Launch ASTRO, ASCO, Quality Oncology Practice Initiative, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

Smith and Nephew's Episode of Care Assurance Program (eCAP) reduces hospital readmission following total joint replacement surgery
LONDON, Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces results showing a near 75% decrease in readmission rates for joint arthroplasties (TJA) conduct... Devices, Orthopaedic Smith & Nephew, Episode of Care Assurance Program, total joint arthroplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

Aquestive Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Clobazam Oral Soluble Film to Treat Lennox-Gastaut Syndrome
WARREN, N.J., Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Aquestive Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application for clobazam Oral Soluble Fil... Biopharmaceuticals, Drug Delivery Aquestive Therapeutics, clobazam, Oral Soluble Film, Lennox-Gastaut syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

Bluegrass Vascular Announces Enrollment Of First Patients In U.S. Pivotal Trial
SAN ANTONIO, Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access, today announced the enrollment of its f... Devices, Interventional Bluegrass Vascular Technologies, Surfacer System, Surfacer Inside-Out (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

Lannett Names Timothy C. Crew To Board Of Directors
PHILADELPHIA, Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that Timothy C. Crew, the company's recently appointed chief executive officer (CEO), has been added to the Lannett Company Board of... Biopharmaceuticals, Generic, Personnel Lannett Company (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2018 Category: Pharmaceuticals Source Type: news

Avion Pharmaceuticals announces approval of first NDA in the oral contraceptive category
ATLANTA, Jan. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Avion Pharmaceuticals, LLC, the makers of the Prenate® line of prescription prenatal vitamins, received approval of its new drug application (NDA) for the oral contraceptive Balcoltra... Biopharmaceuticals, FDA Avion Pharmaceuticals, Balcoltra, levonorgestrel, ethinyl estradiol (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

Catalyst OrthoScience Strengthens Its Board of Directors with The Addition of Greg Rainey
NAPLES, Fla., Jan. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Catalyst OrthoScience, Inc., a cutting-edge medical device company focused on the upper extremity orthopedics market, today announced the addition of Greg Rainey to its Board of Dire... Devices, Orthopaedic, Personnel Catalyst OrthoScience, Total Shoulder, stemless (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

International Biophysics obtains FDA 510k clearance for the FloPump(R) 32 centrifugal heart pump
AUSTIN, Texas, Jan. 17, 2018 -- (Healthcare Sales & Marketing Network) -- International Biophysics Corporation, a global medical device manufacturer based in Austin, Texas, announced they have received FDA 510k clearance for their FloPump 32 centrifugal d... Devices, Cardiology, FDA International Biophysics, FloPump 32, disposable heart pump (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Agreement positions company to advance dextromethadone program to its full potential targeting a wide range of neurological conditions including certain rare genetic diseases NEW YORK, Jan. 17, 2018 -- (Healthcare Sales & Marketing Network) -- Relmada ... Biopharmaceuticals, Neurology Relmada Therapeutics, dextromethadone (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted accelerated assessment to Kymriah for children, young adults with ... Biopharmaceuticals, Oncology Novartis, Kymriah, tisagenlecleucel, CAR-T , cell therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST(R) for Prophylaxis of Hereditary Angioedema Attacks
LEIDEN, Netherlands, January 17, 2018 -- (Healthcare Sales & Marketing Network) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announced today that the U.S. Food and Drug Administration (FDA) has accep... Biopharmaceuticals Pharming Group, RUCONEST, hereditary angioedema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2018 Category: Pharmaceuticals Source Type: news

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs
SILVER SPRING, Md., Jan. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Scientific progress and new drug innovation don't take place in a vacuum. The exchange of information that informs decisions to undertake research, invest in new scientific ende... Biopharmaceuticals, FDA clinical trials (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Geoffrey B. Davis Joins GT Biopharma's Board of Directors
LOS ANGELES, January 16, 2018 -- (Healthcare Sales & Marketing Network) -- GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP.PA) today announced that Geoffrey B. Davis will join GT Biopharma's Board of Directors effective immediately. Mr. Davis is... Biopharmaceuticals, Oncology, Personnel GT Biopharma, Natural Killer Cell Engagers, antibody-drug conjugate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Sequence Bio appoints Dr. Michael S. Phillips as Chief Scientific Officer to lead genomic research and drug discovery projects
Genomics expert Dr. Phillips will lead Sequence Bio's scientific efforts to understand and cure diseases using genomic and longitudinal health data from - and for the benefit of - the Newfoundland and Labrador population ST. JOHN'S, Jan. 16, 2018 -- (He... Biopharmaceuticals, Personnel Sequence Bio (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
End of Phase 2 Meeting Scheduled for HDV in February 2018 Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., Jan. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focuse... Biopharmaceuticals Eiger BioPharmaceuticals, pulmonary arterial hypertension, ubenimex (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
Company makes solid progress in advancing discussions with multiple third parties in the evaluation of strategic options that are expected to unlock significant value Management on track to execute value-driving corporate and clinical milestones in the ... Biopharmaceuticals, Oncology MabVax Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials Partner/Out-license robust dermatology and ophthalmology franchises to strengthen the Company's balan... Biopharmaceuticals, Oncology RXi Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1) Data support findings from the CLEAR study, which found... Biopharmaceuticals Novartis, Cosentyx, secukinumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news